Generate Biomedicines Inc. shares slumped 21% in the company’s trading debut after it raised $400 million in an initial public offering. Shares of the Somerville, Massachusetts-based drug developer ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Jon has been an author at Android Police since 2021. He primarily writes features and editorials covering the latest Android news, but occasionally reviews hardware and Android apps. His favorite ...

Security experts warn against using AI-generated passwords after finding predictable patterns in outputs from ChatGPT, Gemini, and Claude that make them vulnerable to attacks. PCWorld reports that AI ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 million in an initial public offering, as listing activity in ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...

The era of AI has not been particularly great for cybersecurity. We know that vibe-coded websites and apps have been a hotbed of security flaws that leave the platforms vulnerable to attacks. It turns ...

Add Yahoo as a preferred source to see more of our stories on Google. Researchers have demonstrated a particulate static effect-induced electricity generation technology inspired by the Tesla turbine.

Creating strong passwords means balancing security with memorability, so your accounts stay safe without needing a sticky note on your monitor. Password security tips now favor passphrases—long ...

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...

Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. The Flagship-founded biotech has yet to set out how many ...